Dare Bioscience Files Prospectus Related To The Resale Of Up To 8,934,345 Shares Of Common Stock By Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1401914/000149315226040265/forms-1.htm
Read original at benzingaStocks · News reference
Dare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 55.56 percent increase over losses of $(0.45) per share from
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 8:02 PM
- Checked
- Aug 13, 2026, 8:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Daré Bioscience Announces Publication Of Clinical Study Results From Its Proprietary Formulation Of Topical Sildenafil Cream, 3.6%, In Menopause In The Journal Of The Menopause Society; 3.6% Was Well Tolerated Across All Evaluated Doses In The Clinical Study, With Minimal Systemic Exposure
The peer-reviewed article, titled, "A phase 1, open-label, within-participant dose-escalation study to evaluate the safety and pharmacokinetics of topical sildenafil cream in healthy postmenopausal women,"
Read original at benzinga8-K filing — Dare Bioscience, Inc. (DARE)
Filed: 2026-08-17 AccNo: 0001493152-26-038649 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
Read original at benzinga